Ubs Group Ag Ani Pharmaceuticals Inc Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Ani Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Group Ag holds 264,390 shares of ANIP stock, worth $17.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

264,390

Previous 594,810 55.55%

Holding current value

$17.5 Million

Previous $32.9 Million 46.17%

% of portfolio

0.0%

Previous 0.01%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$53.93 - $68.36 $17.8 Million - $22.6 Million	-330,420 Reduced 55.55%	264,390 $17.7 Million
Q4 2024 Feb 14, 2025	BUY	$53.35 - $61.74 $16.4 Million - $19 Million	308,322 Added 107.62%	594,810 $32.9 Million
Q3 2024 Nov 14, 2024	BUY	$54.33 - $65.72 $13.8 Million - $16.7 Million	254,514 Added 796.0%	286,488 $17.1 Million
Q2 2024 Aug 13, 2024	BUY	$58.53 - $68.82 $849,387 - $998,715	14,512 Added 83.11%	31,974 $2.04 Million
Q1 2024 May 13, 2024	SELL	$54.2 - $69.69 $85,039 - $109,343	-1,569 Reduced 8.24%	17,462 $1.21 Million
Q4 2023 Feb 09, 2024	BUY	$48.72 - $65.43 $626,198 - $840,971	12,853 Added 208.04%	19,031 $1.05 Million
Q3 2023 Nov 09, 2023	SELL	$50.28 - $64.61 $1.3 Million - $1.67 Million	-25,895 Reduced 80.74%	6,178 $358,000
Q2 2023 Aug 11, 2023	BUY	$37.29 - $53.83 $759,821 - $1.1 Million	20,376 Added 174.2%	32,073 $1.73 Million
Q1 2023 May 12, 2023	BUY	$37.61 - $45.72 $183,536 - $223,113	4,880 Added 71.59%	11,697 $464,000
Q4 2022 Feb 08, 2023	BUY	$31.9 - $41.95 $216,058 - $284,127	6,773 Added 15393.18%	6,817 $274,000
Q3 2022 Nov 10, 2022	BUY	$29.83 - $38.01 $1,312 - $1,672	44 New	44 $1,000
Q2 2022 Aug 10, 2022	SELL	$23.09 - $33.46 $11,106 - $16,094	-481 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$26.91 - $47.15 $145,852 - $255,553	-5,420 Reduced 91.85%	481 $14,000
Q4 2021 Feb 14, 2022	BUY	$32.97 - $56.85 $140,913 - $242,976	4,274 Added 262.69%	5,901 $273,000
Q3 2021 Nov 15, 2021	SELL	$26.48 - $35.99 $19,409 - $26,380	-733 Reduced 31.06%	1,627 $53,000
Q2 2021 Aug 13, 2021	SELL	$31.86 - $38.6 $51,071 - $61,875	-1,603 Reduced 40.45%	2,360 $83,000
Q1 2021 May 12, 2021	SELL	$28.4 - $36.14 $29,252 - $37,224	-1,030 Reduced 20.63%	3,963 $144,000
Q4 2020 Feb 11, 2021	SELL	$23.69 - $31.47 $70,785 - $94,032	-2,988 Reduced 37.44%	4,993 $145,000
Q3 2020 Nov 12, 2020	SELL	$26.38 - $33.1 $264,037 - $331,297	-10,009 Reduced 55.64%	7,981 $226,000
Q2 2020 Jul 31, 2020	BUY	$29.93 - $50.1 $310,463 - $519,687	10,373 Added 136.18%	17,990 $581,000
Q1 2020 May 01, 2020	SELL	$30.35 - $67.14 $229,992 - $508,786	-7,578 Reduced 49.87%	7,617 $311,000
Q4 2019 Feb 14, 2020	BUY	$55.65 - $79.83 $307,243 - $440,741	5,521 Added 57.07%	15,195 $937,000
Q3 2019 Nov 14, 2019	BUY	$64.7 - $85.39 $348,344 - $459,739	5,384 Added 125.5%	9,674 $706,000
Q2 2019 Aug 14, 2019	BUY	$67.77 - $82.2 $282,600 - $342,774	4,170 Added 3475.0%	4,290 $353,000
Q1 2019 May 14, 2019	SELL	$45.83 - $70.54 $4,491 - $6,912	-98 Reduced 44.95%	120 $8,000
Q4 2018 Feb 14, 2019	SELL	$41.17 - $56.44 $63,237 - $86,691	-1,536 Reduced 87.57%	218 $10,000
Q3 2018 Nov 14, 2018	BUY	$52.95 - $71.34 $57,450 - $77,403	1,085 Added 162.18%	1,754 $99,000
Q2 2018 Aug 14, 2018	SELL	$56.38 - $68.08 $47,077 - $56,846	-835 Reduced 55.52%	669 $45,000
Q1 2018 May 15, 2018	BUY	$56.98 - $72.41 $68,831 - $87,471	1,208 Added 408.11%	1,504 $88,000
Q4 2017 Feb 14, 2018	SELL	$53.3 - $74.56 $133,036 - $186,101	-2,496 Reduced 89.4%	296 $19,000
Q3 2017 Nov 14, 2017	BUY	$43.46 - $52.49 $24,250 - $29,289	558 Added 24.98%	2,792 $147,000
Q2 2017 Aug 14, 2017	SELL	N/A	-2,378 Reduced 51.56%	2,234 $105,000
Q1 2017 Nov 14, 2017	BUY	N/A	4,612	4,612 $228,000

Others Institutions Holding ANIP

# of Institutions

239

Shares Held

19.9M

Call Options Held

7.4K

Put Options Held

12.4K

View Full List

About ANI PHARMACEUTICALS INC

Ticker ANIP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 17,426,000
Market Cap $1.16B
Description
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose produc...

More about ANIP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account